Tal Danino

This paper develops a tumor-targeting engineered bacterium that improves therapeutic efficacy and safety in cancer treatment.

This paper engineers probiotic bacteria to target granulomas and reduce mycobacterial infection in vitro and in vivo.

The paper introduces NanoPro, a nanovector therapy platform using probiotically-released tumor-binding tags to target antigenically indistinct tumors, demonstrating in vitro efficacy with high transduction rates.

This paper develops a bacterial platform that combines enzyme/prodrug chemotherapy and immunotherapy to enhance antitumor responses with improved safety in a murine tumor model.

This study shows engineered E. coli expressing CXCL13 enhances bladder cancer immunotherapy when combined with PD-1 blockade by promoting tumor-specific antibody responses.

This paper describes engineered bacteria that deliver a viral genome to initiate oncolytic infection in tumors, demonstrating bacterial control over viral replication.

This study engineers probiotic E. coli to deliver neoantigen peptides, enhancing T cell immunity and reducing tumor growth in mice.

This study engineers a probiotic bacteria to selectively target pancreatic cancer, improving survival and modulating the tumor microenvironment.

This paper engineers bacterial swarm patterns to record environmental inputs using a deep learning model and segmentation approach.

This paper develops a programmable probiotic encapsulation system using synthetic biology to enhance therapeutic delivery in mice by controlling bacterial immunogenicity and survivability.

This study uses single-cell imaging to show alphavirus superinfection exclusion is a graded, bidirectional process rather than a binary one, revealing a passive mechanism.

The paper designs a probiotic platform to deliver checkpoint blockade nanobodies to tumors using a controlled lysing mechanism for therapeutic release.

This study engineers bacteria to sense and grow in response to specific environmental cues, improving targeted colonization in the gastrointestinal tract.

This paper demonstrates that engineered bacteria can deliver immunotherapeutic payloads to induce durable tumor regression and systemic antitumor immunity.

The paper presents a 3-D multicellular model to rapidly screen engineered microbial therapies, identifying effective antitumor candidates and demonstrating scalability across microbial species.

The paper identifies two new plasmid post-segregational killing mechanisms in E. coli that enhance plasmid stability in both in vitro and in vivo settings.